Meet And Network With The Key Influencers Shaping The Law, Policy And Proceedings of Paragraph IV Litigation
Each spring, leading pharmaceutical patent litigators for brand name and generic drug companies gather at the Paragraph IV Disputes conference to discuss, debate, and analyze the latest trends, judicial rulings and legislative developments affecting Hatch-Waxman litigation.
As the industry prepares to address the fall out of global pharmaceutical patent losses of billions of dollars on the Hatch-Waxman landscape, the time for this conference has never been more relevant.
REGISTER NOW with IP Watchdog 10% discount code: D10-999-IPW20
The 2020 Agenda Features:
FIRESIDE CHAT WITH THE FEDERAL CIRCUIT
Exclusive interview with the Hon. Kathleen M. O’Malley, United States Circuit Judge
DISTRICT COURT INSIGHTS
Interactive discussions with District Court Judges and Magistrate Judges from D.N.J.; D. Del.; E.D. Pa.; E.D. Tex.
SPECIAL FOCUS SESSIONS ON THE PTAB
APJs Roundtable and advanced discussions on policy, practice, procedure, and the Appointments Clause
FTC KEYNOTE ADDRESS
Insights on antitrust developments impacting brands and generics
FDA THINK TANK
Now Confirmed: Representatives from United States Food and Drug Administration
• Grail Sipes, Deputy Center Director for Regulatory Policy, CDER
• Maryll Toufanian, Director, FDA Office of Generic Drug Policy, CDER
FOUR NEW BREAKOUT TRACKS
Featuring an In-House Solutions Studio and Litigators War Room
EXTENDED NETWORKING BREAKS
Connect and reconnect with industry colleagues and establish